Drug Profile
Clevudine - Bukwang Pharmaceutical
Alternative Names: L-FMAU; Levovir; RevovirLatest Information Update: 26 Sep 2022
Price :
$50
*
At a glance
- Originator Bukwang
- Developer Bukwang Pharmaceutical; Eisai Co Ltd; Pharmasset
- Class Antivirals; Arabinonucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B
- Phase II COVID 2019 infections